Logo
  • Home
  • About
  • What we do
  • Partners
  • News
  • Resources
  • Careers
  • Contact

08 Aug 2022  |  News

The first step in the journey from imprecise drug therapy to precision medicine – REPO4EU

By Kathryn Morrissey for BioLizard

BioLizard is proud to join the REPO4EU consortium.

The consortium of REPO4EU (Precision drug REPurpOsing For EUrope and the world) is pleased to announce the launch of an ambitious joint initiative selected and granted almost €23M by the European Commission as part of the Horizon Europe Programme.

REPO4EU’s ultimate goal is to build and grow an industry-level European online platform for validated precision drug repurposing with a global reach. This platform will operate as the go-to data hub for key information, training resources, matchmaking and cooperation in drug repurposing.

The platform will provide extensive expertise throughout the whole value chain in drug repurposing: from freedom-to-operate analysis to intellectual property protection and business development, health technology assessment, ethics and data governance considerations.

During the next 7 years, 28 partners from 10 countries (The Netherlands, Germany, Austria, Spain, Sweden, Romania, Belgium, Portugal, Switzerland and the United States) will join forces to make REPO4EU a reality and create a unique platform for drug repurposing, pooling stakeholders and expertise at a global stage to create a “made in Europe”, fully-fledged infrastructure for drug repurposing.

 

Drug repurposing

But what exactly is drug repurposing? To answer this question, there is first a need to address the elephant in the room: to this day, we still rely on 19th-century disease definitions – often named after specific organs, symptoms or even doctors –, when it has become painfully obvious that trying to compartmentalize the human body into small, completely isolated parts with no connection to one another is an extremely naïve endeavour.

The truth is that our disease definitions are no longer valid – and the end of medicine as we know it is quickly approaching.

Even though we have witnessed an exponential increase in the volume of drug discovery investments since the 80s, overall efficacy has stagnated in the pharmaceutical sector – there is currently no way of differentiating between patients who will benefit and those who will not, and unwanted side effects cannot be predicted reliably.

The reason? There is a conceptual problem in how we define diseases and, consequently, in the way we currently approach drug development. Most underlying disease mechanisms are not understood and are thus rather treated symptomatically in an imprecise manner.

 

Systems Medicine is organ-agnostic

This philosophy lies at the core of what we call systems medicine: the ambition to map the full network of human diseases – the so-called diseasome – to unravel the hidden connections between mechanistically similar diseases. In the diseasome, diseases appear in clusters, indicating a common genetic origin through shared risk genes. These clusters radically change what we call a disease: now, the underlying causal molecular mechanism becomes our disease definition.

It all comes down to a very simple thought: if we can understand the underlying mechanisms that govern a specific disease, surely, we can repurpose drugs for another disease that shares some of those common elements?

The answer is yes! Mechanism-based drug repurposing will revolutionize the way we approach drugs – it will help us find new uses for already registered drugs, increase precision and radically cut down on costs and time in the drug development process – jumping straight into clinical trials that are small, precise, innovatively designed and compliant with the highest safety and operational excellence standards.

 

Curing diseases with high precision

Chronic diseases are only chronic because we do not know how to cure them yet. REPO4EU’s organ-agnostic approach will push drug repurposing to its full potential by mixing Big Data, Artificial Intelligence-driven bioinformatics and Network Science with advanced cheminformatics to redefine diseases in a mechanism-based manner and repurpose drugs beyond their original target.

REPO4EU will thereby unlock unprecedented breakthroughs in precision, efficacy and cost-effectiveness.

 

A resource for researchers, companies, healthcare providers, payers, and patients

Whether you need to secure bioinformatics support for an unmet medical need, explore a registered compound or a specific mechanism; assess your freedom to operate, outline a patenting strategy or browse regulatory advice; liaise with a business partner, locate a clinical trial test site for phase I-III or craft a business plan… we have the experts and the experience to help you!

 

RExPO22 – The 1st International Conference on Drug Repurposing

REPO4EU will officially start this September and what better way to kick things off than with a high-profile conference? We are delighted to present RExPO22, the very first instalment in our RExPO series of international conferences on drug repurposing.

Networking has always been the prime focus of any scientific and business event and this one is both: high-impact science and innovative business. Come join us on September 2nd -3 rd at Maastricht for two days of vibrant keynotes from world-renowned experts and busy discussion around the future of drug repurposing!

 

 

Key contacts

Coordinator: Prof. Dr. Harald HHW Schmidt, Maastricht University, hschmidt@ppmlab.net

Communication: Diana Lopez, AUSTRALO, diana@australo.org

Project management office: Miriam Simon, concentris, miriam.simon@concentris.de

Related news

portfolio
25 July 2022

BioLizard is now an Official Illumina Connected Analytics Implementation Partner

BioLizard is recognised as a skilled and competent service partner for ICA users.  

Read more
portfolio
19 January 2022

BioLizard enters into a strategic partnership with flanders.bio

We’re proud to officially announce that BioLizard begins its strategic partnership with flanders.bio.

Read more
portfolio
15 December 2021

BioLizard partners up with AutoML provider JADBio

BioLizard partners with JADBio, a leading provider of automated machine learning (AutoML) tools.  

Read more
portfolio
19 October 2021

BioLizard joins the at.las ATMP community

We’re proud to join the at.las ATMP community!

Read more

Let's do something
great together

Contact us

Join the social
media discussion

Stay informed with
our latest news

Read our news
  • Home
  • About

©2022 BioLizard nv. All Rights Reserved. Design by Just Jax. Development by TYL.

  • Privacy Policy
Logo
Biolizard Cookie Consent Information

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.

Cookie SettingsAccept All

Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
bcookie2 yearsLinkedIn sets this cookie from LinkedIn share buttons and ad tags to recognize browser ID.
langsessionThis cookie is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc1 dayLinkedIn sets the lidc cookie to facilitate data center selection.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_gtag_UA_164325847_11 minuteThis cookie is set by Google and is used to distinguish users.
_gat_UA-164325847-11 minuteThis is a pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites.
_gcl_au3 monthsProvided by Google Tag Manager to experiment advertisement efficiency of websites using their services.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
CookieDurationDescription
_fbp3 monthsThis cookie is set by Facebook to display advertisements when either on Facebook or on a digital platform powered by Facebook advertising, after visiting the website.
bscookie2 yearsThis cookie is a browser ID cookie set by Linked share Buttons and ad tags.
fr3 monthsFacebook sets this cookie to show relevant advertisements to users by tracking user behaviour across the web, on sites that have Facebook pixel or Facebook social plugin.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
CookieDurationDescription
a3aa548f857642d7ad9818410843280acd93d104c52e466aa7c59da011282bb01 yearNo description
AnalyticsSyncHistory1 monthNo description
li_gc2 yearsNo description
UserMatchHistory1 monthLinkedin - Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
SAVE & ACCEPT
Powered by CookieYes Logo